The clinical development of a 5 alpha-reductase inhibitor, finasteride.
about
5alpha-reductase: history and clinical importanceLY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complexAndrogen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survivalMechanistic Pathways of Sex Differences in Cardiovascular Disease.Androgens induce nongenomic stimulation of colonic contractile activity through induction of calcium sensitization and phosphorylation of LC20 and CPI-17.Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins.Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.Finasteride and Male Breast Cancer: Does the MHRA Report Show a Link?Benign Prostatic Hyperplasia Implications for Pharmacologic Treatment and Perioperative Care.The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride.Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats.Anti-androgens for the treatment of hirsutism.A new look at the 5alpha-reductase inhibitor finasteride.The role of intraprostatic inflammation in the acute urinary retentionActivation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.Lower urinary tract disease: what are we trying to treat and in whom?PC-SPES: a brief overview.PSA measurement in the treatment of BPH.Preventing diseases of the prostate in the elderly using hormones and nutriceuticals.Prostate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia--a pilot studyThe physiological basis of human sexual arousal: neuroendocrine sexual asymmetry.Role of 5 alpha-reductase inhibitors in the management of prostate cancer.Identification and selective inhibition of an isozyme of steroid 5 alpha-reductase in human scalp.Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride.Finasteride.Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?NSAIDs induce apoptosis in nonproliferating ovarian cancer cells and inhibit tumor growth in vivo.Finasteride-its impact on sexual function and prostate cancer.Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.Clomiphene citrate rescue of spermatogenesis in men with infertility while remaining on finasteride: A case reportThe benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism.Etifoxine stimulates allopregnanolone synthesis in the spinal cord to produce analgesia in experimental mononeuropathy.Lower urinary tract symptoms in benign prostatic hyperplasia patients: orchestrated by chronic prostatic inflammation and prostatic calculi?.The effect of finasteride on spermatogenesis of Mesocricetus auratus.Development of liposomal systems of finasteride for topical applications: design, characterization, and in vitro evaluation.Safety and efficacy of a novel Prunus domestica extract (Sitoprin, CR002) on testosterone-induced benign prostatic hyperplasia (BPH) in male Wistar rats.Fibrillar collagen genes are not coordinately upregulated with TGF β1 expression in finasteride-treated prostate.Expression profiles of reproduction- and thyroid hormone-related transcripts in the brains of chemically-induced intersex frogs.
P2860
Q24546176-1E494ACC-8DEA-47AF-B51B-9C0779D6E5FAQ24562777-EBC0A0AD-0751-43AA-BA39-9CD77BFA7870Q24658019-BD6DA0C1-8403-4CE8-9B8C-E8EE7029F012Q24793296-C983C14D-AFF0-41D7-B6AB-431666207E99Q30241924-7D37266A-0DAA-4E10-8FFE-A8B4472B0982Q33637557-CF4050AD-F17D-4307-A723-D37FF3A6E011Q33803717-AD2FD1F9-90BF-40D3-88C8-AA8B37A624F2Q34110419-54E588DD-1C0A-4EE9-A636-2BB9F762E8A5Q34209875-0A8993EF-B0C6-45A0-8AC5-E33728D2D066Q34338110-AF2B41E4-04C2-4400-AA84-80AC35183B35Q34350952-599421E1-40AB-433C-8687-CC1D2AED6ABEQ34418086-96915EFC-DE93-4C21-9A82-A10AC0BE8F04Q34470170-D611CE0D-13E4-4E7B-A7EE-3425E663CE7CQ34544658-5855351C-6B64-460D-B9A9-4EB912F6D881Q34546591-B8AD6FCD-F6D7-45CD-AC21-420AE5386D2CQ34714167-FBB36D2D-BEF2-45E4-8180-EA730B7216A4Q34786897-133D0152-50A0-46FD-BF68-B0DD62230921Q35545715-853C271B-F22D-4789-BC00-88266F816EE2Q35604672-B31F49BD-2A50-48D8-BB8D-6F3D1C31E963Q35685846-0955B949-3452-441A-B2C7-076844253599Q36021075-68090D17-56A6-4C11-A951-CA8DF4390798Q36041671-E8EDA893-CD79-42A6-B251-3F8536AE4D0AQ36089403-F567F4C2-0A93-4F9D-860F-21D56E1F5FECQ37018960-81BDAFB8-4555-4F4E-A1CF-63D04988B4D4Q37297335-37F8AA47-B63A-44D6-8DA3-5524F1E04470Q37694089-F52B6FB4-A343-48A9-AE5A-C54655A151FBQ37763952-117666EA-62C6-4AFE-9AC0-15C387EFD0A8Q38571198-ECDFC649-D25B-43E1-B427-A58CD0F8094EQ39350226-88BE4304-2980-4D65-80B9-5B96632A7360Q39681594-83FA14F2-E7B7-46A2-928F-096D5D9ACFF2Q40286042-171CF2E6-6A35-4D5A-9840-1DEA06E21F8EQ42314376-A192B8D5-9DEF-441C-BDC1-90A384DEC862Q44424880-EF2DBC9F-88EC-49E2-B477-3973604F2FC7Q45785693-7F453A7D-1804-4D30-B661-5C3DB632D85BQ45903672-4E1CBF50-9FF9-4948-8D0E-911FCF41B742Q46540978-38EDC6EF-D9C5-43BF-A52F-D23D8BA60603Q46831436-5D54D97F-CA47-42D8-8CFE-1B2C0BD4EE27Q49980853-FBD7586C-277B-4668-AB97-629F7718AB71Q51008917-811394E3-A733-4EE4-923D-D53DB3725D47Q51519600-3D5754C4-B61C-4D65-92E7-B1671E21D604
P2860
The clinical development of a 5 alpha-reductase inhibitor, finasteride.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
The clinical development of a 5 alpha-reductase inhibitor, finasteride.
@ast
The clinical development of a 5 alpha-reductase inhibitor, finasteride.
@en
type
label
The clinical development of a 5 alpha-reductase inhibitor, finasteride.
@ast
The clinical development of a 5 alpha-reductase inhibitor, finasteride.
@en
prefLabel
The clinical development of a 5 alpha-reductase inhibitor, finasteride.
@ast
The clinical development of a 5 alpha-reductase inhibitor, finasteride.
@en
P1476
The clinical development of a 5 alpha-reductase inhibitor, finasteride.
@en
P2093
P304
P356
10.1016/0960-0760(90)90487-6
P577
1990-11-01T00:00:00Z